BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting

Richard A Scolyer; Victoria Atkinson; David Gyorki; Duncan Lambie; Sandra O’Toole; Robyn P.M. Saw; Benhur Amanuel; Christopher Angel; Alison Button‐Sloan; Matteo S. Carlino; Sydney Ch’ng; Andrew J. Colebatch; Dariush Daneshvar; Inês Pires da Silva; Tamara Dawson; Peter M. Ferguson; Erwin Foster‐Smith; Stephen B. Fox; Anthony J. Gill; Ruta Gupta; Michael A. Henderson; Angela Hong; Julie R. Howle; Louise Jackett; Craig James; C. Soon Lee; Alistair Lochhead; Daphne Loh; Grant A. McArthur; Catriona McLean; Alexander M. Menzies; Omgo E. Nieweg; Blake O’Brien; Thomas E. Pennington; Alison J. Potter; Saurabh Prakash; Robert V. Rawson; Rebecca L. Read; Michael Rtshiladze; Kerwin F. Shannon; B. Mark Smithers; Andrew J. Spillane; Jonathan R. Stretch; John F. Thompson; Paul Tucker; Alexander H. R. Varey; Ricardo E. Vilain; Benjamin A. Wood; Georgina V. Long

doi:10.1016/j.pathol.2021.11.002

Related publications

Article2012

BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma

Graham J. Mann, Gulietta M. Pupo, Anna Campain, Candace D. Carter, Sarah‐Jane Schramm, Svetlana Pianova, Sebastien K. Gerega, Chitra De Silva, Kenneth Lai, James S. Wilmott, Maria Synnott, Peter Hersey, Richard Kefford, John F. Thompson, Jean Yang, Richard A Scolyer

Article2015

Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma.

Jennifer A. Wargo, Rodabe N. Amaria, Merrick I. Ross, Robyn P.M. Saw, Jeffrey E. Gershenwald, Patrick Hwu, Sapna P. Patel, Isabella Claudia Glitza, Adi Diab, Richard Kefford, Richard A Scolyer, Helen Rizos, John F. Thompson, Kerwin F. Shannon, Andrew J. Spillane, Matteo S. Carlino, Alex Guminski, Lauren Simpson, Michael A. Davies, Georgina V. Long

Article2021

Management of resected stage III/IV melanoma with adjuvant immunotherapy.

Rebecca Johnson, Victoria Atkinson, Prachi Bhave, Alison M. Weppler, Geoffrey Peters, Afaf Abed, Megan Lyle, Muhammad Adnan Khattak, Andrew Haydon, Matteo S. Carlino, Shahneen Sandhu, Georgina V. Long, Alexander M. Menzies

Article2023

CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.

Peter K. H. Lau, S.J. Harris, Melissa Eastgate, Damien Kee, Andrew Mant, Louise M. Nott, Craig Gedye, Andrisha Jade Inderjeeth, Craig Underhill, Alison M. Weppler, Roslyn Wallace, Belinda Lee, George Au‐Yeung, Narelle Williams, Daniel Ariza Ospino, Louise Gonzales, Mark Shackleton, Serigne Lo, Grant A. McArthur, Shahneen Sandhu

Article2016

BRAF (v600e) and NRAS (q61r/q61l) mutation analysis using immunohistochemistry: Implications for routine mutation testing of melanoma samples

Hojabr Kakavand, Trina Lum, James S. Wilmott, Elizabeth Smith, Sandra O’Toole, Georgina V. Long, Richard A Scolyer